Short Interest in Basilea Pharmaceutica AG (OTCMKTS:BPMUF) Drops By 29.0%

Basilea Pharmaceutica AG (OTCMKTS:BPMUFGet Free Report) was the recipient of a significant decline in short interest in February. As of February 28th, there was short interest totalling 15,700 shares, a decline of 29.0% from the February 13th total of 22,100 shares. Currently, 0.1% of the shares of the stock are sold short. Based on an average daily volume of 0 shares, the days-to-cover ratio is currently ? days.

Basilea Pharmaceutica Price Performance

Shares of BPMUF opened at $52.83 on Monday. The company has a current ratio of 4.10, a quick ratio of 3.27 and a debt-to-equity ratio of 5.70. Basilea Pharmaceutica has a one year low of $38.60 and a one year high of $52.83. The stock has a 50 day moving average price of $52.83 and a 200 day moving average price of $52.49.

Basilea Pharmaceutica Company Profile

(Get Free Report)

Basilea Pharmaceutica AG, a commercial-stage biopharmaceutical company, focuses on the development of products that address the medical needs in the therapeutic areas of oncology and anti-infectives. The company offers Cresemba, an intravenous and antifungal drug for the treatment of invasive aspergillosis and mucormycosis in the United States, and the European Union.

Read More

Receive News & Ratings for Basilea Pharmaceutica Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Basilea Pharmaceutica and related companies with MarketBeat.com's FREE daily email newsletter.